Table 1.

Clinical baseline characteristics of the patients at the time of inclusion in the study

Clinical Baseline CharacteristicsAll PatientsTertile 1 (Low)Tertile 2 (Medium)Tertile 3 (High)P Value Low Versus High
Number of patients118403939
PLA2R-Ab level total IgG (units/ml)300±44355±17141±32711±583<0.001
PLA2R-Ab level IgG4 (units/ml)42.3±65.07.8±5.120.9±13.199.1±88.2<0.001
Males (%)86 (73%)29 (73%)31 (79%)26 (67%)0.86
Age (yr)53.1±16.348.2±15.852.9±15.358.2±16.5<0.01
Time from renal biopsy to first serum measurement (mo)a0.75 (0.25–1.0)0.5 (0.0–0.75)0.75 (0.25–1.0)0.75 (0.25–1.5)0.06
Proteinuria (g/24 h)a7.5 (5.0–10.7)6.4 (4.8–8.7)7.3 (5.8–10.4)9.1 (4.3–12.2)0.07
Serum albumin (g/L)25.7±5.526.6±5.226.3±6.624.3±4.40.04
Serum creatinine (mg/dl)a1.0 (0.8–1.3)1.0 (0.7–1.2)1.1 (0.9–1.3)1.1 (0.9–1.4)0.12
Patients on immunosuppression during follow-up (%)93 (79)26 (65)31 (79)36 (92)0.31
Systolic BP (mmHg)136.1±18.9129.6±18.1138.1±20.5140.7±16.6<0.01
  • Patients were divided in tertiles depending on the total IgG PLA2R-Ab level at the start of the study: tertile 1, low PLA2R-Ab levels; tertile 2, medium PLA2R-Ab levels; tertile 3, high PLA2R-Ab levels. P values are given for the comparison of the patients in tertiles 1 (low PLA2R-Ab levels) and 3 (high PLA2R-Ab levels). PLA2R-Ab, phospholipase A2 receptor autoantibody.

  • a Data are shown as medians and interquartile ranges.